Latest news with #asaMedical
Business Wire
22-05-2025
- Business
- Business Wire
Bayer Launches Centafore Imaging Core Lab to Support Imaging for Clinical Trials and Software as a Medical Device Development
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced the launch of its Imaging Core Lab Services under the brand name Centafore. With over 25 years of experience supporting more than 200 clinical trials at Bayer and its arm's length companies globally, Centafore is now positioned as a distinct Imaging solution provider, offering tailored services for external customers to support their clinical trials and Software as a Medical Device (SaMD) development across diverse therapeutic areas and development phases. Attendees of the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO) will get the chance to learn more about the Centafore team, technology and its services in Chicago from May 30 till June 3 (Booth #24152). Centafore provides technology and services for image management, processing, and interpretation, empowering study sponsors with expert project management and facilitating advanced analyses of imaging data. Its extensive network includes experienced imaging professionals like board-certified radiologists, enabling customers to effectively manage studies across more than 50 countries. 'Centafore represents a significant leap forward in our commitment to enhancing the landscape of clinical trial imaging and advancing the development of new medicines and healthcare solutions,' said Nelson Ambrogio, President of Radiology at Bayer. 'By leveraging our extensive experience and expertise, we are dedicated to providing our customers with high quality imaging services that meet their specific needs in clinical research. Through Centafore, we aim to enhance the reliability of trial outcomes and support informed decision-making in the development of investigational medicines, ultimately benefiting patients and improving their quality of care.' Centafore's services support a wide range of therapeutic areas, including oncology, cardiovascular, CNS, dermatology, women's health, pediatrics, and digital health. It aims to help pharmaceutical, biotech, medical device and digital health companies with early research through Phase IV trials and SaMD development, and adherence to regulatory and data privacy compliance standards. As part of Bayer's ongoing efforts to support global healthcare startups, the Imaging Core Lab Services of Bayer have been first presented at ECR 2024. Centafore is already collaborating with organizations such as OBIO® and Luxsonic Technologies to leverage clinical imaging as a critical tool for improving decision-making in clinical trials and software as a medical device (SaMD) development. About Centafore Centafore is an Imaging Contract Research Organization (iCRO) that supports early research through phase IV trials and Software as a Medical Device (SaMD) development for pharma, biotech, medical device and digital health companies. For over 25 years, it has been the primary, trusted iCRO for Bayer, playing a vital role in advancing the company's drug pipeline – and now, extended its expertise to external customers under the brand name Centafore, delivering high-quality support for imaging studies and research initiatives across the industry. About Bayer in Radiology Building on a century of expertise, Bayer is committed to innovative products and high-quality services in diagnostic imaging to enhance patient care. Its leading radiology portfolio features contrast agents and devices for precise administration across modalities including computed tomography (CT), X-ray and magnetic resonance imaging (MRI), and positron emission tomography (PET). Bayer's comprehensive offerings also include informatics solutions, a curated marketplace with digital and artificial intelligence (AI) enabled applications. In 2024, Bayer's radiology products generated €2.1 billion in global sales. Committed to research and innovation, Bayer continues to advance medical imaging with the ultimate goal to improve patient outcomes. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, 'Health for all, Hunger for none,' the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Yahoo
05-05-2025
- Health
- Yahoo
Dawn Health Secures EURm 11.5 to Scale Platform & Product Suite for Next-Gen Pharma Digital Health Solutions
Press release Dawn Health Secures EURm 11.5 to Scale Platform & Product Suite for Next-Gen Pharma Digital Health Solutions Copenhagen, Denmark – 5th of May, 2025 Dawn Health – a global leader in digital health, co-founded by Trifork and held as a minority investment in Trifork Labs – today announced that the company has secured a funding round of EURm 11.5 from its existing investors: Chr. Augustinus Fabrikker, the Export and Investment Fund of Denmark (EIFO), and Trifork Labs. The investment is aimed at supporting the company's strategy to deliver its platform and product suite to global pharma companies through a SaaS model, while continuing to invest in further offerings within the Dawn Product Suite. Since 2021, Dawn Health has been dedicated to developing a best-in-class platform designed specifically to accommodate the needs and use cases of the pharmaceutical industry. The Dawn Platform and Product Suite have already been widely adopted by five global industry leaders, including Merck and Novartis. The Dawn Platform is currently used in areas such as oncology, multiple sclerosis, and rare pediatric conditions like growth disorders. It helps patients manage their treatment, report symptoms, and stay in close contact with their healthcare team. The Dawn Platform and Product Suite empower pharma companies, patients, and healthcare professionals to improve outcomes and patient care by leveraging advanced capabilities in AI, data, evidence generation, clinical integrations, personalization, and connected health. By improving both data collection and analytics, these capabilities ultimately benefit patients and pharma companies alike, positioning the Dawn Platform as the foundation for therapy companions, disease management programs, and real-world evidence (RWE) solutions that enable the next generation of digital health. 'Our ambition is to be the global leader in digital health, powering pharma's next-generation products – and ultimately improving the lives of patients worldwide,' said Alexander Mandix Hansen, CEO of Dawn Health. 'This funding allows us to bring our proven platform to more markets and deepen our impact.' This next phase reinforces Dawn Health's position as a trusted partner to pharma companies, delivering valuable, scalable, regulatory-grade digital health products that evolve with the needs of modern medicine. 'Since the major investment in December 2021, Dawn Health has grown its revenue significantly and expanded its footprint in global pharma. With more than 100 employees, unique solutions, and a strong regulatory infrastructure, we are prepared to further accelerate our growth,' said Lars Marcher, Chairman of Dawn Health. About Dawn HealthDawn Health is a global leader in digital health, specializing in the development of Software as a Medical Device (SaMD), Digital Therapeutics (DTx), and connected health solutions. Accelerating the launch of digital solutions to market, the Dawn Health product suite drives innovation to change the lives of people with chronic conditions. Through close partnerships with the life sciences industry, Dawn Health creates digital health products that transform patient care through an empathetic and human-centric approach. Learn more at Contact: Christopher Kold, Marketing Manager, cko@ +45 41 58 60 88 About Trifork GroupTrifork is a pioneering global technology partner, empowering enterprise and public sector customers with innovative solutions. With 1,229 professionals across 73 business units in 16 countries, Trifork delivers expertise in inspiring, building, and running advanced software solutions across diverse sectors, including public administration, healthcare, manufacturing, logistics, energy, financial services, retail, and real estate. Trifork Labs, the Group's R&D hub, drives innovation by investing in and developing synergistic and high-potential technology companies. Trifork Group AG is a publicly listed company on Nasdaq Copenhagen. Learn more at Contact: Frederik Svanholm, Group Investment Director, frsv@ +41 79 357 7317 Attachment PR_Labs_Dawn HealthSign in to access your portfolio
